Bioxcel Therapeutics Stock Buy Hold or Sell Recommendation
| BTAI Stock | USD 0.47 0.04 7.84% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding BioXcel Therapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of BioXcel Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out BioXcel Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide. In addition, we conduct extensive research on individual companies such as BioXcel and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
BioXcel |
Execute BioXcel Therapeutics Buy or Sell Advice
The BioXcel recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on BioXcel Therapeutics. Macroaxis does not own or have any residual interests in BioXcel Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BioXcel Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
BioXcel Therapeutics Trading Alerts and Improvement Suggestions
| BioXcel Therapeutics generated a negative expected return over the last 90 days | |
| BioXcel Therapeutics has high historical volatility and very poor performance | |
| BioXcel Therapeutics has some characteristics of a very speculative penny stock | |
| BioXcel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.38 M. Net Loss for the year was (179.05 M) with profit before overhead, payroll, taxes, and interest of 355 K. | |
| BioXcel Therapeutics currently holds about 233.45 M in cash with (155.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| BioXcel Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: BioXcel Therapeutics Announces Pricing of 7.0 Million Public Offering |
BioXcel Therapeutics Returns Distribution Density
The distribution of BioXcel Therapeutics' historical returns is an attempt to chart the uncertainty of BioXcel Therapeutics' future price movements. The chart of the probability distribution of BioXcel Therapeutics daily returns describes the distribution of returns around its average expected value. We use BioXcel Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of BioXcel Therapeutics returns is essential to provide solid investment advice for BioXcel Therapeutics.
| Mean Return | -0.18 | Value At Risk | -9.09 | Potential Upside | 9.62 | Standard Deviation | 6.23 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of BioXcel Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
BioXcel Stock Institutional Investors
| Shares | Goldman Sachs Group Inc | 2024-06-30 | 99 K | Bank Of America Corp | 2024-06-30 | 73.4 K | Virtu Financial Llc | 2024-06-30 | 57.3 K | Hrt Financial Llc | 2024-06-30 | 53 K | Ubs Group Ag | 2024-06-30 | 52.5 K | Arete Wealth Advisors, Llc | 2024-06-30 | 43.5 K | Northern Trust Corp | 2024-09-30 | 40.7 K | Hennion & Walsh Asset Management Inc | 2024-09-30 | 40.1 K | Diversify Wealth Management, Llc | 2024-06-30 | 40 K | Vanguard Group Inc | 2024-09-30 | 1.2 M | Blackrock Inc | 2024-06-30 | 440.7 K |
BioXcel Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Capital Expenditures | 870K | 316K | 445K | 139K | 20K | 19K | |
| Net Income | (33.0M) | (82.2M) | (106.9M) | (165.8M) | (179.1M) | (170.1M) | |
| Investments | (870K) | (316K) | (445K) | (139K) | (20K) | (21K) | |
| Change In Cash | (10.1M) | 180.7M | 19.8M | (39.2M) | (128.5M) | (122.1M) | |
| Net Borrowings | (371K) | 179K | 98.6M | 96.0M | 110.3M | 115.9M | |
| Free Cash Flow | (28.2M) | (66.7M) | (82.6M) | (135.5M) | (155.0M) | (147.3M) | |
| Depreciation | 156K | 188K | 297K | 327K | 318K | 179.3K | |
| Change To Netincome | 3.1M | 14.6M | 19.5M | 18.6M | 21.3M | 22.4M | |
| Other Non Cash Items | 3.5M | 15.0M | 46K | 2.1M | 3.1M | 3.3M | |
| End Period Cash Flow | 32.4M | 213.1M | 233.0M | 193.7M | 65.2M | 122.7M |
BioXcel Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BioXcel Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BioXcel Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BioXcel stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.47 | |
β | Beta against Dow Jones | 2.35 | |
σ | Overall volatility | 6.24 | |
Ir | Information ratio | -0.05 |
BioXcel Therapeutics Volatility Alert
BioXcel Therapeutics is displaying above-average volatility over the selected time horizon. BioXcel Therapeutics is a potential penny stock. Although BioXcel Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in BioXcel Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on BioXcel instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.BioXcel Therapeutics Fundamentals Vs Peers
Comparing BioXcel Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BioXcel Therapeutics' direct or indirect competition across all of the common fundamentals between BioXcel Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as BioXcel Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of BioXcel Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing BioXcel Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BioXcel Therapeutics to competition |
| Fundamentals | BioXcel Therapeutics | Peer Average |
| Return On Equity | -17.67 | -0.31 |
| Return On Asset | -0.64 | -0.14 |
| Operating Margin | (14.89) % | (5.51) % |
| Current Valuation | 86.34 M | 16.62 B |
| Shares Outstanding | 42.75 M | 571.82 M |
| Shares Owned By Insiders | 20.06 % | 10.09 % |
| Shares Owned By Institutions | 8.70 % | 39.21 % |
| Number Of Shares Shorted | 347.08 K | 4.71 M |
| Price To Earning | (2.62) X | 28.72 X |
| Price To Book | 3.97 X | 9.51 X |
| Price To Sales | 9.05 X | 11.42 X |
| Revenue | 1.38 M | 9.43 B |
| Gross Profit | 355 K | 27.38 B |
| EBITDA | (165.42 M) | 3.9 B |
| Net Income | (179.05 M) | 570.98 M |
| Cash And Equivalents | 233.45 M | 2.7 B |
| Cash Per Share | 8.33 X | 5.01 X |
| Total Debt | 101.38 M | 5.32 B |
| Debt To Equity | 0.38 % | 48.70 % |
| Current Ratio | 12.25 X | 2.16 X |
| Book Value Per Share | (1.89) X | 1.93 K |
| Cash Flow From Operations | (155.01 M) | 971.22 M |
| Short Ratio | 0.93 X | 4.00 X |
| Earnings Per Share | (2.04) X | 3.12 X |
| Price To Earnings To Growth | (0.01) X | 4.89 X |
| Target Price | 4.2 | |
| Number Of Employees | 74 | 18.84 K |
| Beta | 0.29 | -0.15 |
| Market Capitalization | 21.76 M | 19.03 B |
| Total Asset | 73.7 M | 29.47 B |
| Retained Earnings | (590.6 M) | 9.33 B |
| Working Capital | 44.88 M | 1.48 B |
| Current Asset | 609.37 K | 9.34 B |
Note: Disposition of 5556 shares by Oneill Vincent of BioXcel Therapeutics at 0.55 subject to Rule 16b-3 [view details]
BioXcel Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BioXcel . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 102814.0 | |||
| Daily Balance Of Power | (0.80) | |||
| Rate Of Daily Change | 0.92 | |||
| Day Median Price | 0.48 | |||
| Day Typical Price | 0.47 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | (0.04) | |||
| Relative Strength Index | 56.15 |
About BioXcel Therapeutics Buy or Sell Advice
When is the right time to buy or sell BioXcel Therapeutics? Buying financial instruments such as BioXcel Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having BioXcel Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Warren Buffett Holdings Thematic Idea Now
Warren Buffett Holdings
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BioXcel Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share 0.074 | Quarterly Revenue Growth 1.416 | Return On Assets (0.64) | Return On Equity (17.67) |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.